The unique effect of remoxipride on dopamine utilization in the basal ganglia.
Fuxe
K
K
Department of Histology and Neurobiology, Karolinska Institutet, Stockholm, Sweden.
Ogren
S O
SO
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism*; D001549:Benzamides / Q000494:pharmacology*; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D009830:Olfactory Bulb / Q000187:drug effects / Q000378:metabolism; D011699:Putamen / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D017330:Remoxipride; D013239:Stereotyped Behavior / Q000187:drug effects
D014150:Antipsychotic Agents; D001549:Benzamides; D017330:Remoxipride; D001058:Apomorphine; D004298:Dopamine